Drug name - Rozlytrek
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9029356 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
| US8299057 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Mar, 2029
(6 years from now) | |
| US9085565 | GENENTECH INC | Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(10 years from now) | |
| US10738037 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(14 years from now) | |
| CN106167485A | GENENTECH INC | Acetamidobenzamide, Compositions Containing Acetamidobenzamide And Preparation Method Of Acetamidobenzamide |
Feb, 2020
(2 years ago) | |
| CN103923072A | GENENTECH INC | Substituted Indazole Derivatives Active As Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| CN101754956B | GENENTECH INC | Substituted Indazole Derivatives Having Activity Of Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| CN101754956A | GENENTECH INC | Substituted Indazole Derivatives Active As Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| CN103923072B | GENENTECH INC | Substituted Indazole Derivatives Active As Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| CN104395308B | GENENTECH INC | N - [3 - (5, 5-Difluoro-Benzyl)--1H - Indazole - -3 - Yl] -4-(4-Methyl-Piperazine - -1 - Yl)--2-(Tetrahydro-Pyran - -4 - Ylamino) - Benzamide Preparation Method |
May, 2033
(10 years from now) | |
| CN104395308A | GENENTECH INC | N - [3 - (5, 5-Difluoro-Benzyl)--1H - Indazole - -3 - Yl] -4-(4-Methyl-Piperazine - -1 - Yl)--2-(Tetrahydro-Pyran - -4 - Ylamino) - Benzamide Preparation Method |
May, 2033
(10 years from now) | |
| CN109153669B | GENENTECH INC | New Crystal Form Of Benzamide Compound |
May, 2037
(14 years from now) | |
| CN109153669A | GENENTECH INC | N - [5 - (3, 5-Difluoro-Benzyl) -1H - Indazol - -3 - Yl]--4-(4-Methyl-Piperazin - -1 - Yl)--2-(Tetrahydropyran - -4 - Ylamino) - Form |
May, 2037
(14 years from now) | |
| IN201000870P4 | GENENTECH INC | Substituted Indazole Derivatives Active As Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| IN281852B | GENENTECH INC | Substituted Indazole Derivatives Active As Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| IN361050B | GENENTECH INC | Process For The Preparation Of N-[5-(3-5-Difluoro Benzyl)-1H-Indazol 3 Yl]- 4-(4 Methyl Piperazin -1- Yl) -2- (Tetrahydro Pyran -4- Ylamino) Benzamide |
May, 2033
(10 years from now) | |
| IN201409107P4 | GENENTECH INC | Process For The Preparation Of N [5 (3 5 Difluoro Benzyl) 1H Indazol 3 Yl] 4 (4 Methyl Piperazin 1 Yl) 2 (Tetrahydro Pyran 4 Ylamino) Benzamide |
May, 2033
(10 years from now) | |
| EP2855460A1 | GENENTECH INC | Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide |
Oct, 2017
(4 years ago) | |
| EP2176231A1 | GENENTECH INC | Substituted Indazole Derivatives Active As Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| EP2176231B1 | GENENTECH INC | Substituted Indazole Derivatives Active As Kinase Inhibitors |
Jul, 2028
(5 years from now) | |
| EP3290414B1 | GENENTECH INC | Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide |
May, 2033
(10 years from now) | |
| EP3290414A1 | GENENTECH INC | Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide |
May, 2033
(10 years from now) | |
| EP3333166B1 | GENENTECH INC | Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide |
May, 2033
(10 years from now) | |
| EP3333166A1 | GENENTECH INC | Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide |
May, 2033
(10 years from now) | |
| EP3464276A1 | GENENTECH INC | New Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydropyran-4-Ylamino)-Benzamide |
May, 2037
(14 years from now) | |
| EP3464276B1 | GENENTECH INC | New Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydropyran-4-Ylamino)-Benzamide |
May, 2037
(14 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9255087 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
| US9616059 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
| US9085558 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
| US8673893 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(5 years from now) | |
| US9649306 | GENENTECH INC | Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(10 years from now) | |
| US10231965 | GENENTECH INC | Molecules for administration to ROS1 mutant cancer cells |
Feb, 2035
(12 years from now) | |
| US10561651 | GENENTECH INC | Methods for treating neuroblastoma |
Feb, 2035
(12 years from now) | |
| US11091469 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(14 years from now) | |
| US10398693 | GENENTECH INC | Pharmaceutical compositions and dosage forms |
Jul, 2038
(15 years from now) | |
Drugs and Companies using ENTRECTINIB ingredient
Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; treatment of ros1-positive non-small cell lung cancer; Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of neuroblastomas that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of ros1-positive non-small cell lung cancer; treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 100MG | CAPSULE;ORAL | Prescription |
| 200MG | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.